Atropos Therapeutics

senescence modulation, phenotypic screening, ATRX

modulatingsmall molecule

atroposthera.com·San Francisco, California, United States·

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-XZWC

Summary · Eternal Search editorial

Atropos Therapeutics senescence modulation, phenotypic screening, ATRX

Atropos Therapeutics aims to treat aging-related diseases and cancer and improve healthspan with approved novel senescence-targeting drugs. Its FATES platform is a cell-based phenotypic screening platform based on detecting de novo ATRX foci. The company describes applications in aging through senosuppressors and oncology through senostimulators.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite17

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Atropos Therapeutics — Far from goals · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: exploratory. Band: far. Modifiers: +5 depth (4 programs at exploratory).…

Source: Deterministic

At a glance

Webatroposthera.com

HQSan Francisco, California, United States

Publications

7 on file

012018CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought—→022018PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence—→032017ATRX is a regulator of therapy induced senescence in human cells—→042017Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors—→052016Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice—→062015MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition—→072011Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders—→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Atropos Therapeutics

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.